Novartis' oral multiple sclerosis drug meets main goal in late stage studies
01/09/2026 08:10
Novartis' oral multiple sclerosis drug meets main goal in late stage studies LONDON, Sept 1 (Reuters) - Swiss drugmaker Novartis NOVN.S said on Tuesday that its oral drug, remibrutinib, met the main goals in two late-stage studies, showing superiority over a rival drug in reducing relapse rates in patients with a form of multiple sclerosis.
Investors have been on the lookout for data from three experimental drugs - pelacarsen, multiple sclerosis drug remibrutinib and genetic therapy del-desiran - which together represent more than $10 billion in peak annual sales potential and are drivers of Novartis' long-term growth.
(Reporting by Bhanvi Satija; Editing by Sharon Singleton)
((Bhanvi.Satija@thomsonreuters.com; +44 7920644259;))
Recent news on Novartis AG
See all newsNovartis AG expected to post earnings of $2.27 a share - Earnings Preview
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination (updated)
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Brief: Novartis Receives European Commission Approval For Cosentyx
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant